司库奇尤单抗治疗中重度头皮银屑病的3b期随机对照研究
这项24周双盲3b期研究纳入102例中重度头皮银屑病患者,按1:1随机接受司库奇尤单抗300mg或安慰剂。第12周司库奇尤单抗组PSSI 90应答率52.9% vs 安慰剂2.0%,IGA 0/1应答率56.9% vs 5.9%,完全清除率35.3% vs 0%,差异均显著(P<.001)。安全性与此前3期研究一致。
要点
- 司库奇尤单抗300mg显著改善中重度头皮银屑病,第12周PSSI 90达52.9%。
- 第12周头皮完全清除率35.3%,安慰剂组为0%。
- PSSI评分50%下降的中位时间为3.29周。
核心结论
- 司库奇尤单抗对广泛中重度头皮银屑病患者有效且耐受性良好。
研究设计与样本
- 24周随机双盲安慰剂对照3b期研究,102例患者按1:1随机分组。
- 司库奇尤单抗300mg皮下注射于基线、第1、2、3周,第4至20周每4周一次。
主要发现
- 第12周PSSI 90应答率司库奇尤单抗组52.9% vs 安慰剂组2.0%(P<.001)。
- 第12周IGA modified 2011头皮0/1应答率56.9% vs 5.9%(P<.001)。
- 第12周头皮银屑病完全清除率35.3% vs 0%(P<.001)。
- PSSI评分下降50%的中位时间为3.29周(司库奇尤单抗300mg组)。
- 安全性特征与此前3期研究一致。
关键数值与推荐
- 主要疗效指标为第12周PSSI评分较基线改善90%(PSSI 90)。
临床怎么用
- 司库奇尤单抗300mg可用于中重度头皮银屑病且无中重度躯体银屑病的患者。
局限性
- 研究未设阳性对照臂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Moderate-to-severe scalp psoriasis has not been evaluated in prospective trials of patients without moderate-to-severe body psoriasis. OBJECTIVE: Evaluate the efficacy and safety of secukinumab in moderate-to-severe scalp psoriasis. METHODS: In this 24-week, double-blind, phase 3b study, 102 patients were randomized 1:1 to subcutaneous secukinumab 300 mg or placebo at baseline, weeks 1, 2, and 3, and then every 4 weeks from week 4 to 20. The primary efficacy variable was 90% improvement of Psoriasis Scalp Severity Index (PSSI 90) score from baseline to week 12. RESULTS: At week 12, PSSI 90 (secukinumab 300 mg vs placebo, 52.9% vs 2.0%) and Investigator's Global Assessment modified 2011 scalp responses of 0 or 1 (secukinumab 300 mg vs placebo, 56.9% vs 5.9%) were significantly greater with secukinumab 300 mg than placebo (P < .001 for both). In addition, significantly more patients achieved complete clearance of scalp psoriasis at week 12 with secukinumab 300 mg than placebo (35.3% vs 0%; P < .001). The median time to 50% reduction in PSSI score was 3.29 weeks with secukinumab 300 mg. The safety profile of secukinumab was consistent with previous phase 3 studies. LIMITATIONS: There was no active comparator arm. CONCLUSION: Secukinumab is efficacious and well-tolerated for patients with extensive moderate-to-severe scalp psoriasis.
引用
- Bagel J, Duffin KC, Moore A, et al. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. J Am Acad Dermatol. 2017. PMID: 28780364. doi:10.1016/j.jaad.2017.05.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。